Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

PMID:
25187697
[PubMed - in process]
Free PMC Article
2.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.

Oncoimmunology. 2014 May 14;3:e28861. eCollection 2014.

PMID:
25057448
[PubMed]
Free PMC Article
3.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

PMID:
22829237
[PubMed]
Free PMC Article
4.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

PMID:
22251709
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes.

Ohyashiki M, Ohyashiki JH, Hirota A, Kobayashi C, Ohyashiki K.

Immun Ageing. 2011 Nov 15;8(1):11. doi: 10.1186/1742-4933-8-11.

PMID:
22082184
[PubMed]
Free PMC Article
6.

Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, Tanaka M, Kuroda M, Ohyashiki JH.

PLoS One. 2011 Feb 24;6(2):e16408. doi: 10.1371/journal.pone.0016408.

PMID:
21383985
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.

Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K.

BMC Res Notes. 2010 Dec 24;3:347. doi: 10.1186/1756-0500-3-347.

PMID:
21182798
[PubMed]
Free PMC Article
8.

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.

Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K.

Adv Appl Bioinform Chem. 2008;1:85-98. Epub 2008 Oct 30.

PMID:
21918608
[PubMed]
Free PMC Article
9.

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.

Hamamura RS, Ohyashiki JH, Kurashina R, Kobayashi C, Zhang Y, Takaku T, Ohyashiki K.

Br J Cancer. 2007 Oct 22;97(8):1099-105. Epub 2007 Sep 25.

PMID:
17895889
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection.

Zhang Y, Ohyashiki JH, Takaku T, Shimizu N, Ohyashiki K.

Br J Cancer. 2006 Feb 27;94(4):599-608.

PMID:
16449999
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells.

Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, Ohyashiki K.

Br J Cancer. 2005 May 23;92(10):1942-7.

PMID:
15827550
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Hisatomi H, Ohyashiki K, Ohyashiki JH, Nagao K, Kanamaru T, Hirata H, Hibi N, Tsukada Y.

Neoplasia. 2003 May-Jun;5(3):193-7.

PMID:
12869302
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk